Form 4: Xenon CEO Mortimer Reports RSU Vesting, Tax-Related Share Sale

Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, reported the vesting of 12,500 restricted share units and a subsequent sale of 7,308 common shares to cover tax obligations.

Summary

• Ian Mortimer, President & CEO and Director of Xenon Pharmaceuticals Inc. (XENE), reported transactions related to his beneficial ownership.
• On March 12, 2026, 12,500 Restricted Share Units (RSUs) granted on March 12, 2025, vested, resulting in the acquisition of 12,500 common shares.
• The RSU award vests 25% on each of the first four anniversaries of the grant date, beginning March 12, 2026.
• On March 13, 2026, Mr. Mortimer sold 7,308 common shares at a price of $55.225 per share.
• This sale was executed under a Rule 10b5-1 trading arrangement, adopted on December 3, 2025, specifically to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Mortimer directly beneficially owns 19,923 common shares and indirectly owns 14,300 common shares through his spouse.
• He also beneficially owns 37,500 derivative securities in the form of Restricted Share Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The RSU vesting is a positive for executive compensation and alignment, but the subsequent sale is a routine tax-related event and does not indicate a change in company fundamentals or management's outlook.

Positives

• The vesting of 12,500 Restricted Share Units (RSUs) indicates a component of long-term incentive compensation for the President & CEO, aligning management's interests with shareholder value creation.
• The RSU award structure, vesting 25% annually over four years, demonstrates a commitment to long-term retention and performance.

Negatives

• The sale of 7,308 common shares, even for tax purposes, reduces the direct equity stake of the President & CEO in the company.

Future Outlook

NA

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly 'sell-to-cover' sales executed under a pre-arranged Rule 10b5-1 plan, are common occurrences in the biotechnology and pharmaceutical industry. These transactions are typically routine and are not usually interpreted as a signal of management's sentiment regarding the company's future performance, as they are pre-scheduled to manage tax liabilities associated with equity compensation.

Corporate Governance

Related Party Transactions

• Ian Mortimer's indirect beneficial ownership of 14,300 common shares is held by his spouse, which is a standard disclosure for related party holdings.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction for tax purposes, not indicative of a change in company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Share Units and a subsequent 'sell-to-cover' sale for tax purposes, executed under a pre-arranged Rule 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or performance. Therefore, a seasoned investor would likely maintain their current position, as this filing provides no new material information to warrant a change in investment strategy.

Keywords

Xenon Pharmaceuticals, XENE, Ian Mortimer, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Stock Sale, Tax Withholding, Rule 10b5-1 Plan